On December 11, the 2025 Shenzhen International High-Performance Medical Device and Innovative Medicine Exhibition (Hong Kong Station) was successfully held in Kowloon, Hong Kong. The event was guided by the Shenzhen Municipal Development and Reform Commission, the Health Bureau of the Hong Kong Special Administrative Region, the Health Commission of Shenzhen Municipality, and the Shenzhen Municipal Healthcare Security Administration. It was jointly organized by the Shenzhen Biomedical Promotion Association, the Shenzhen Biomedical Industry Alliance, the Shenzhen Society for Life Sciences and Biotechnology, the Hong Kong Association for Biomedical Innovation, and the Hong Kong Biotechnology Organization. Professor Shi Yuanyuan, Chairman of Cell Valley Group, was invited to attend the event, where he signed a significant strategic cooperation agreement and delivered a keynote speech.

During the strategic signing ceremony, a series of landmark achievements in Shenzhen-Hong Kong collaboration were officially unveiled, becoming the focal point of the event.Deep Harbour Cell Valley Healthcare and Technology Co., Ltd., a subsidiary of Cell Valley Group, formally signed an agreement with the Hong Kong Institute of Cell and Gene Therapy. Both parties will jointly establish the Hong Kong Cell and Gene Therapy Service Platform. In the future, this platform will build an integrated system for research and translation, consolidating the industrial strengths of both regions and unleashing a synergistic effect where "1+1 > 2".

Following the signing ceremony, Chairman Shi Yuanyuan delivered a keynote speech titled "Current Status and Prospects of Cell Therapy" at a sub-forum. He provided an in-depth analysis of the breakthrough potential inherent in cell and gene therapy as a pioneering therapeutic modality of the 21st century within the global medical frontier. Professor Shi also elaborated on the "dual-track" management model adopted for cell therapy under the guidance of Order No. 818 issued by the State Council. He emphasized that cell therapy is poised to reshape the industry landscape as a New Biomedical Technology, and his insights garnered significant attention from the audience.